COMMUNIQUÉS West-GlobeNewswire

Une nouvelle étude sur EggNest® publiée dans JAHA et une dérogation réglementaire au Texas confirment l’évolution vers des procédures sans tablier plombé en salle de cardiologie interventionnelle
22/10/2026
MINNEAPOLIS, 22 oct. 2026 (GLOBE NEWSWIRE) -- Egg Medical a annoncé aujourd’hui la publication d’une étude prospective dans le Journal of the American Heart Association (JAHA), évaluant ses dispositifs renforcés de [...]
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
22/10/2026
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission [...]
Pharming Group announces third quarter 2026 revenues above market expectations
22/10/2026
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
22/10/2026
Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% ( [...]
Ipsen réalise une croissance remarquable des ventes au cours des neuf premiers mois de 2026 et relève à nouveau ses prévisions pour l’exercice en cours
22/10/2026
Croissance du chiffre d’affaires du Groupe de 24,6 % à taux de change constant 1 (TCC) au cours des neuf premiers mois de l’année 2026 ou 23,0 % en données publiées, avec une croissance du portefeuille stratégique 2 de [...]
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
22/10/2026
Year-to-date total sales growth of 24.6% at CER 1 , or 23.0% as reported, with the core portfolio 2 achieving sales growth of 24.2% 1 Further upgraded FY 2026 financial guidance: total sales growth around 23.0% at CER ( [...]
Persica Pharmaceuticals presents antibiotic exposure-response analysis at the International Society of Pain & Neuroscience (ISPN) Annual Conference
22/10/2026
London, UK, 22 October 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today [...]
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
22/10/2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological [...]
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
22/10/2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological [...]
Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
22/10/2026
HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Asimov Announces Adoption of Its AI-Driven Cell Line Development Platform by LG Chem
22/10/2026
Asimov’s CHO Edge System, including the recently announced Chrysalis transposase and Kernel, Asimov’s AI-driven genetic design software, will support LG Chem’s biologics cell line development activities BOSTON, Oct. 21 [...]
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
22/10/2026
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, [...]
Cytokinetics to Announce Third Quarter Results on November 4, 2026
21/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. [...]
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
21/10/2026
WESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
BioCryst to Report Third Quarter 2026 Financial Results on November 4
21/10/2026
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November [...]
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
21/10/2026
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food [...]
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
21/10/2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for [...]
Seer to Report Third Quarter 2026 Financial Results on November 10, 2026
21/10/2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
21/10/2026
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare [...]

Pages